LIfT BioSciences Secures Record €12M Grant To Launch Human Cancer Trials

Unlike traditional treatments that aim to fix damaged immune systems, LIfT’s method replaces them entirely. The company grows powerful neutrophil cells from rare “super donors” whose immune systems naturally fight cancer. These cells, called IMANs (Immuno-Modulatory Alpha Neutrophils), are given to patients via IV.

IMANs are specially engineered to attack solid tumours, especially those that no longer respond to existing treatments. They work by killing cancer cells in a broad, non-specific way and reshaping the tumour environment to trigger a stronger immune response.

Read Also - Trustfull Raises €6M To Drive European expansion

The trial will start with small patient groups to find the safest and most effective dose, which will then be used alongside checkpoint inhibitors in further testing. The results will support the therapy’s development and boost investment in LIfT’s Galway operations.

The grant will also fund a partnership with the University of Galway and Hooke Bio—who will contribute clinical trial expertise and advanced tools to study patient responses.

Alex Blyth, Chief Executive Officer of LIfT Biosciences, said: “LIfT Biosciences isn’t just developing a new ‘blockbuster’ drug. We’re creating a whole new way of thinking about the body – not just killing the cancer but helping the body to fight back. By harnessing the power of a few extraordinary immune systems, we’re working to bring that power to everyone.

This grant from the DTIF allows us to take another step forward in bringing our treatment to the masses – something we’re truly striving for and believe everyone should have access to.”

The Disruptive Technologies Innovation Fund (DTIF) is a €500 million challenge-based fund created under Project Ireland 2040. It is one of four funds established through the National Development Plan (2018–2027), managed by the Department of Enterprise, Trade and Employment and administered by Enterprise Ireland.

Commenting on the award, Peter Burke, Minister for Enterprise, Tourism and Employment, said “We want to fund projects that will make a real difference to people’s lives.

The N-LIfT project has come through a rigorous evaluation process and the level of funding awarded reflects its potential to be a game-changer in cancer therapy. I’m excited to see the impact it will deliver.”

About LIfT BioSciences

Founded in 2016, LIfT BioSciences is developing alpha neutrophil cell therapies to treat solid tumours by directly attacking cancer and reprogramming the immune response. Its patented N-LIfT platform uses engineered stem cells to create CAR-IMANs with enhanced cancer-killing power, aiming for full remission across solid tumours by 2030.